Illes Pernod, Sylvain Belisle, Normand Blais, Fanny Bonhomme, Annie Borel-Derlon, Jeanne-Yvonne > Open

Illes Pernod, Sylvain Belisle, Normand Blais, Fanny Bonhomme, Annie Borel-Derlon, Jeanne-Yvonne Borg, Jean-Luc Bosson, Jean-Philippe Collet, Emmanuel De Maistre, Philippe De Moerloose, Pierre Fontana, Yves Gruel, Joanne Guay, Yann Huet, Brigitte Ickx, Brigitte Jude, Dominique Lasne, Dan Longrois, Jean-Fran is Hardy, Emmanuel Marret, Patrick Mismetti, Serge Motte, Nathalie Nathan, Nadia Rosencher, Charles Marc Samama, Laurence Jesel-Morel, Jean-Francois Schved, Sylvie Schlumberger, Pierre Sie, Sophie Susen, Philippe Van der Linden, Andr?Vincentelli, Paul Zufferey, Ariel Cohen, Juan V. Llau Pitarch, Eric Vanbelle, Gregoire Legal, Sylvie Laporte, Thomas Pierre Lecompte, Yves Ozier, Philippe Nguyen, Stephanie Roullet, David FaraoniAuthor information Section of Anesthesiology, Peri-operative and Agony Medicine, Boston Kid's Healthcare facility, Harvard Clinical Faculty, Boston, MA 02115, United states. two Section of Anesthesiology and Intense Treatment, Duke University School of medicine, Durham, NC 27710, United states. 3Department of Anesthesiology and Intensive PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/16505107 Treatment Drugs, Grenoble College Hospital, Grenoble 38043, France. 4Department of Anesthesiology and Intensive Care Drugs, Support Publique- H itaux de Paris, Cochin College Medical center, Paris 75181, France.References 1. Levy JH, Critical NS, Azran MS. Novel oral anticoagulants: implications while in the perioperative setting. Anesthesiology. 2010;113:726?5. 2. Levy JH, Faraoni D, Spring JL, Douketis JD, Samama CM. Taking care of new oral anticoagulants while in the perioperative and intensive care unit location. 2-(2-Aminoethoxy)-5-chloropyridine hydrochloride Anesthesiology. 2013;118:1466?four. three. Majeed A, 2-(5-Bromo-2-chlorophenyl)acetonitrile Hwang HG, Connolly SJ, Eikelboom JW, Ezekowitz MD, Wallentin L, et al. Administration and outcomes of main bleeding in the course of treatment with dabigatran or warfarin. Circulation. 2013;128:2325?2. 4. Beyer-Westendorf J, Forster K, Pannach S, Ebertz F, Gelbricht V, Thieme C, et al. Costs, management and result of bleeding problems throughout rivaroxaban treatment in each day treatment: results in the Dresden NOAC registry. Blood. 2014;124:955?two. five. Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S, et al. Periprocedural bleeding and thromboembolic events with dabigatran PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/25116583 in comparison with warfarin: benefits in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized demo. Circulation. 2012;126:343?. 6. Beyer-Westendorf J, Gelbricht V, F ster K, Ebertz F, K ler C, Werth S, et al. Peri-interventional management of novel oral anticoagulants in every day treatment: outcomes with the prospective Dresden NOAC registry. Eur Coronary heart J. 2014;35:1888?6. seven. Levy JH. Purpose of coagulation component concentrates for reversing dabigatran-related anticoagulation. Anesthesiology. 2014;120:1316?. eight. Faraoni D, Samama CM, Ranucci M, Dietrich W, Levy J. Perioperative management of new oral anticoagulants: a world study. Clinics Lab Med. 2014;34:637?4. nine. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. European Coronary heart Rhythm Affiliation functional guideline on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013;15:625?1. ten. Stangier J, Rathgen K, St le H, Mazur D. Impact of renal impairment around the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre examine. Clin Pharmacokinet. 2010;forty nine:259?8. 11. Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, et al. The impact of dabigatran plasma concentrations and client attributes over the f.